159 related articles for article (PubMed ID: 34820552)
41. The Harmonious Interplay of Amino Acid and Monocarboxylate Transporters Induces the Robustness of Cancer Cells.
Yoshida GJ
Metabolites; 2021 Jan; 11(1):. PubMed ID: 33401672
[TBL] [Abstract][Full Text] [Related]
42. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB
Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J
J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556
[TBL] [Abstract][Full Text] [Related]
43. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
[TBL] [Abstract][Full Text] [Related]
44. Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.
Ueno S; Kimura T; Yamaga T; Kawada A; Ochiai T; Endou H; Sakurai H
J Pharmacol Sci; 2016 Jun; 131(2):110-7. PubMed ID: 27262901
[TBL] [Abstract][Full Text] [Related]
45. Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth.
Cormerais Y; Giuliano S; LeFloch R; Front B; Durivault J; Tambutté E; Massard PA; de la Ballina LR; Endou H; Wempe MF; Palacin M; Parks SK; Pouyssegur J
Cancer Res; 2016 Aug; 76(15):4481-92. PubMed ID: 27302165
[TBL] [Abstract][Full Text] [Related]
46. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
47. The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer.
Lu X
Curr Cancer Drug Targets; 2019; 19(11):863-876. PubMed ID: 31376820
[TBL] [Abstract][Full Text] [Related]
48. Biomarker Analyses in Patients With Advanced Solid Tumors Treated With the LAT1 Inhibitor JPH203.
Okano N; Hana K; Naruge D; Kawai K; Kobayashi T; Nagashima F; Endou H; Furuse J
In Vivo; 2020; 34(5):2595-2606. PubMed ID: 32871789
[TBL] [Abstract][Full Text] [Related]
49. Targeting amino acid metabolism for cancer therapy.
Lukey MJ; Katt WP; Cerione RA
Drug Discov Today; 2017 May; 22(5):796-804. PubMed ID: 27988359
[TBL] [Abstract][Full Text] [Related]
50. Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
Muto Y; Furihata T; Kaneko M; Higuchi K; Okunushi K; Morio H; Reien Y; Uesato M; Matsubara H; Anzai N
Anticancer Res; 2019 Jan; 39(1):159-165. PubMed ID: 30591453
[TBL] [Abstract][Full Text] [Related]
51. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
52. Protein turnover, ureagenesis and gluconeogenesis.
Schutz Y
Int J Vitam Nutr Res; 2011 Mar; 81(2-3):101-7. PubMed ID: 22139560
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.
Yothaisong S; Dokduang H; Anzai N; Hayashi K; Namwat N; Yongvanit P; Sangkhamanon S; Jutabha P; Endou H; Loilome W
Tumour Biol; 2017 Mar; 39(3):1010428317694545. PubMed ID: 28347255
[TBL] [Abstract][Full Text] [Related]
54. ATB
Lou D; Lou Z; Lin Y; Shangguan H; Lin Y; Luo Q; Zhang H; Lin G; Chen R; Kou L; Bao S
Bioorg Med Chem Lett; 2021 Feb; 33():127728. PubMed ID: 33346010
[TBL] [Abstract][Full Text] [Related]
55. Potent-By-Design: Amino Acids Mimicking Porous Nanotherapeutics with Intrinsic Anticancer Targeting Properties.
Wu Z; Lim HK; Tan SJ; Gautam A; Hou HW; Ng KW; Tan NS; Tay CY
Small; 2020 Aug; 16(34):e2003757. PubMed ID: 32686344
[TBL] [Abstract][Full Text] [Related]
56. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
Nachef M; Ali AK; Almutairi SM; Lee SH
Front Immunol; 2021; 12():624324. PubMed ID: 33953707
[TBL] [Abstract][Full Text] [Related]
57. Glutamine Transport and Mitochondrial Metabolism in Cancer Cell Growth.
Scalise M; Pochini L; Galluccio M; Console L; Indiveri C
Front Oncol; 2017; 7():306. PubMed ID: 29376023
[TBL] [Abstract][Full Text] [Related]
58. Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.
Imami K; Sugiyama N; Imamura H; Wakabayashi M; Tomita M; Taniguchi M; Ueno T; Toi M; Ishihama Y
Mol Cell Proteomics; 2012 Dec; 11(12):1741-57. PubMed ID: 22964224
[TBL] [Abstract][Full Text] [Related]
59. Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment.
Hayashi K; Anzai N
World J Gastrointest Oncol; 2017 Jan; 9(1):21-29. PubMed ID: 28144396
[TBL] [Abstract][Full Text] [Related]
60. Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin.
Rink JS; Yang S; Cen O; Taxter T; McMahon KM; Misener S; Behdad A; Longnecker R; Gordon LI; Thaxton CS
Mol Pharm; 2017 Nov; 14(11):4042-4051. PubMed ID: 28933554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
